Eli Lilly Enters R&D and Licensing Deal with Haisco, Up to $3 Billion in Milestones
Reported by Reuters
Sentiment
Positive
Importance
7
Price
$1,096.15
Mkt Cap
$1.041T
52W Low
$623.78
52W High
$1,149.1
Market data snapshot near publication time
Summary
Eli Lilly has signed a licensing and R&D collaboration agreement with Haisco Pharmaceutical. The deal includes up to $87 million in upfront and near-term payments to Haisco, with potential for an additional $3.0 billion in subsequent milestone payments. This expands Eli Lilly's research pipeline, adding a new development program.
At the time of this announcement, LLY was trading at $1,096.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,149.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.
Price Chart
LLY - Latest Insights
LLY
Jun 01, 2026, 12:36 PM EDT
LLY
Jun 01, 2026, 12:26 PM EDT
LLY
Jun 01, 2026, 4:49 AM EDT
LLY
May 29, 2026, 3:14 AM EDT
LLY
May 28, 2026, 3:41 PM EDT
LLY
May 28, 2026, 3:26 PM EDT
LLY
May 27, 2026, 3:14 AM EDT
LLY
May 26, 2026, 6:45 AM EDT
LLY
May 25, 2026, 9:24 AM EDT
LLY
May 23, 2026, 3:13 AM EDT